← All Allogene Therapeutics, INC filings

Allogene Therapeutics, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
ALLO
Allogene Therapeutics, INC
10-K: Allogene Therapeutics 2025 Annual Report: Clinical Progress & Financials
Allogene Therapeutics reports a $190.9 million net loss in 2025, advancing its allogeneic CAR T pipeline with key clinical milestones expected in 2026 and 2027, while managing operational risks and capital needs.
NASDAQ
ALLO
Allogene Therapeutics, INC
10-K: Allogene Therapeutics Focuses on Key Programs, Reports $257.6 Million Net Loss in 2024
Allogene Therapeutics prioritizes its LBCL, autoimmune disease, and RCC programs while reporting a $257.6 million net loss for the year ended December 31, 2024.
NASDAQ
ALLO
Allogene Therapeutics, INC
10-K: Allogene Therapeutics Restates Financials, Prioritizes First-Line Lymphoma Trial
Allogene Therapeutics restated prior financials due to an accounting error and is now focusing on a pivotal Phase 2 trial for its CAR T-cell therapy in first-line lymphoma treatment.
NASDAQ
ALLO
Allogene Therapeutics, INC
10-K/A: Allogene Therapeutics Restates Financials Following SEC Comment on Joint Venture Accounting
Allogene Therapeutics has amended its annual report to restate financial statements due to an SEC comment regarding accounting for a joint venture, impacting revenue and expense recognition.